1. Home
  2. MBIO vs SPHL Comparison

MBIO vs SPHL Comparison

Compare MBIO & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBIO
  • SPHL
  • Stock Information
  • Founded
  • MBIO 2015
  • SPHL 2002
  • Country
  • MBIO United States
  • SPHL Singapore
  • Employees
  • MBIO N/A
  • SPHL N/A
  • Industry
  • MBIO Biotechnology: Pharmaceutical Preparations
  • SPHL Homebuilding
  • Sector
  • MBIO Health Care
  • SPHL Consumer Discretionary
  • Exchange
  • MBIO Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • MBIO 4.7M
  • SPHL 4.9M
  • IPO Year
  • MBIO N/A
  • SPHL 2024
  • Fundamental
  • Price
  • MBIO $1.72
  • SPHL $0.65
  • Analyst Decision
  • MBIO
  • SPHL
  • Analyst Count
  • MBIO 0
  • SPHL 0
  • Target Price
  • MBIO N/A
  • SPHL N/A
  • AVG Volume (30 Days)
  • MBIO 105.9K
  • SPHL 3.4M
  • Earning Date
  • MBIO 11-07-2025
  • SPHL 10-28-2025
  • Dividend Yield
  • MBIO N/A
  • SPHL N/A
  • EPS Growth
  • MBIO N/A
  • SPHL N/A
  • EPS
  • MBIO N/A
  • SPHL N/A
  • Revenue
  • MBIO N/A
  • SPHL $5,956,226.00
  • Revenue This Year
  • MBIO N/A
  • SPHL N/A
  • Revenue Next Year
  • MBIO N/A
  • SPHL N/A
  • P/E Ratio
  • MBIO N/A
  • SPHL N/A
  • Revenue Growth
  • MBIO N/A
  • SPHL N/A
  • 52 Week Low
  • MBIO $0.89
  • SPHL $0.35
  • 52 Week High
  • MBIO $21.95
  • SPHL $7.80
  • Technical
  • Relative Strength Index (RSI)
  • MBIO 58.12
  • SPHL 63.26
  • Support Level
  • MBIO $1.54
  • SPHL $0.52
  • Resistance Level
  • MBIO $1.63
  • SPHL $0.85
  • Average True Range (ATR)
  • MBIO 0.08
  • SPHL 0.09
  • MACD
  • MBIO 0.01
  • SPHL 0.01
  • Stochastic Oscillator
  • MBIO 75.50
  • SPHL 59.30

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: